scholarly journals Photopheresis Provides Significant Long-Lasting Benefit in Nephrogenic Systemic Fibrosis

2017 ◽  
Vol 2017 ◽  
pp. 1-4
Author(s):  
Ranran Zhang ◽  
William Nicholas Rose
Keyword(s):  
Renal Function ◽  
Contrast Agents ◽  
Nephrogenic Systemic Fibrosis ◽  
Rare Complication ◽  
Nephrogenic Fibrosing Dermopathy

Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is a rare complication of exposure to gadolinium-based contrast agents in patients who have significantly decreased renal function. Manifestations include fibrosis of the skin and other tissues. Effective therapies are lacking. Photopheresis has been tried with variable rates of improvement, and small numbers of cases (20 as of 2016) have been reported of NSF patients treated with photopheresis. We report a case of patient with nephrogenic systemic fibrosis who was treated with photopheresis and demonstrated significant lasting improvements.

scholarly journals Nephrogenic systemic fibrosis: concepts and perspectives

2012 ◽  
Vol 87 (4) ◽  
pp. 597-607 ◽  
Author(s):  
Ana Carolina de Souza Machado Igreja ◽  
Kleyton de Carvalho Mesquita ◽  
Shawn Edwin Cowper ◽  
Izelda Maria Carvalho Costa
Keyword(s):  
Magnetic Resonance Imaging ◽  
Renal Failure ◽  
Renal Function ◽  
Contrast Agents ◽  
Nephrogenic Systemic Fibrosis ◽  
Clinicopathological Correlation ◽  
Resonance Imaging ◽  
Skin Changes ◽  
Preventive Methods

Nephrogenic systemic fibrosis is a chronic, progressive condition that develops in some patients with renal impairment after exposure to gadolinium-based contrast agents used in magnetic resonance imaging. Thickening of the skin is typical, usually affecting the extremities. Visceral organs can also be affected. The diagnosis of the disease requires careful clinicopathological correlation. Treatment aims at restoring renal function, which is associated with delayed progression and, eventually, remission of skin changes. Reduction and prevention of nephrogenic systemic fibrosis cases are based on limiting the use of gadolinium-based contrast agents in patients with kidney disorders (especially in patients with advanced renal failure at stages 4 and 5), and restricting their use to situations in which they are essential to diagnosis/follow-up. Other than limiting exposure to gadolinium based contrast agents, no effective preventive methods have been reported. Due to increased awareness about the disease among radiologists and nephrologists, the incidence of nephrogenic systemic fibrosis is declining.

Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis

Radiology ◽  
2007 ◽  
Vol 242 (3) ◽  
pp. 647-649 ◽  
Author(s):  
Phillip H. Kuo ◽  
Emanuel Kanal ◽  
Ali K. Abu-Alfa ◽  
Shawn E. Cowper
Keyword(s):  
Contrast Agents ◽  
Nephrogenic Systemic Fibrosis ◽  
Mr Contrast Agents

scholarly journals Changes in Urinary and Serum Levels of Novel Biomarkers after Administration of Gadolinium-based Contrast Agents

2016 ◽  
Vol 11 ◽  
pp. BMI.S39199 ◽  
Author(s):  
Habib Mawad ◽  
Louis-Philippe Laurin ◽  
Jean-François Naud ◽  
François A. Leblond ◽  
Nathalie Henley ◽  
...  
Keyword(s):  
Renal Function ◽  
Contrast Agents ◽  
Cystatin C ◽  
Normal Renal Function ◽  
Serum Levels ◽  
Serum Cystatin C ◽  
Baseline Serum ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Novel Biomarkers ◽  
Neutrophil Gelatinase

Objective The aim of our study is to describe the changes in urinary and serum levels of novel biomarkers after gadolinium contrast administration in patients with normal renal function. Methods We measured four biomarkers in 28 volunteers: interleukin-18 (IL-18), N-acetyl-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin, and cystatin C. Urinary and serum samples were collected at 0, 3, and 24 hours following gadolinium administration. Results Baseline serum creatinine was 57.8 ± 34.5 μmol/L and remained stable. Urinary IL-18 levels increased significantly at three hours (10.7 vs. 7.3 ng/mg creatinine; P < 0.05). Similarly, urinary NAG levels increased significantly at three hours (3.9 vs. 2.2 IU/mg creatinine; P < 0.001). For both these markers, the difference was no longer significant at 24 hours. No statistically significant differences were observed for urinary and serum neutrophil gelatinase-associated lipocalin levels and for serum cystatin C levels. Conclusions Urinary IL-18 and NAG levels increased transiently after administration of gadolinium-based contrast agents in patients with normal renal function.

Screening Breast MRI and Gadolinium Deposition: Cause for Concern?

2021 ◽  
Author(s):  
Colleen H Neal
Keyword(s):  
Breast Cancer ◽  
Renal Function ◽  
Contrast Agents ◽  
Biological Significance ◽  
Breast Mri ◽  
Reliable Data ◽  
Breast Cancer Data ◽  
Cancer Data ◽  
Contrast Enhanced ◽  
Gadolinium Retention

Abstract Gadolinium-based contrast agents (GBCAs) have been used worldwide for over 30 years and have enabled lifesaving diagnoses. Contrast-enhanced breast MRI is frequently used as supplemental screening for women with an elevated lifetime risk of breast cancer. Data have emerged that indicate a fractional amount of administered gadolinium is retained in the bone, skin, solid organs, and brain tissues of patients with normal renal function, although there are currently no reliable data regarding the clinical or biological significance of this retention. Linear GBCAs are associated with a higher risk of gadolinium retention than macrocyclic agents. Over the course of their lives, screened women may receive high cumulative doses of GBCA. Therefore, as breast MRI screening utilization increases, thoughtful use of GBCA is indicated in this patient population.

Sign in / Sign up

Export Citation Format

Share Document